Drugs by condition
Drugs approved for fabry disease
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
3
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
3
New molecular entities and new biologics
In development
7
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for fabry disease.
- Elfabrio (Pegunigalsidase Alfa-Iwxj) · Chiesi Farmaceutici Spa NovelPriority reviewMay 9, 2023
- Galafold (Migalastat Hydrochloride) · Amicus Therap US NovelAccelerated approvalPriority reviewOrphanAug 10, 2018
- Fabrazyme (Agalsidase Beta) · Genzyme NovelAccelerated approvalPriority reviewOrphanApr 24, 2003
All approved drugs for fabry disease, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for fabry disease
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- VenglustatGZ402671Phase 35 trials
Sanofi · Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1
- LucerastatPhase 32 trials
Idorsia Pharmaceuticals Ltd. · Fabry Disease
- 4D-310Phase 22 trials
4D Molecular Therapeutics · Fabry Disease
- AMT-191Phase 21 trial
UniQure Biopharma B.V. · Fabry Disease
- EXG110Phase 21 trial
Guangzhou Jiayin Biotech Ltd · Fabry Disease
- HM15421GC1134APhase 21 trial
GC Biopharma Corp · Fabry Disesase
- ST-920Phase 21 trial
Sangamo Therapeutics · Fabry Disease
More on fabry disease: recruiting trials · published research
Related in rare and genetic disease: Transthyretin amyloidosis · Hereditary angioedema · Gaucher disease · Pompe disease · Phenylketonuria (PKU) · Achondroplasia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.